RESUMEN
PURPOSE: At the time of castration resistance, it is recommended to realize hormonal manipulations before chemotherapy. We evaluated the impact of a switch from GnRH agonist to antagonist in patients with castration-resistant prostate cancer on PSA and testosterone levels at 3 months. METHODS: Retrospectively, 17 patients from 5 different centers undergoing androgen deprivation therapy and presenting rising PSA confirmed on 3 blood samples 2 weeks apart and despite a castrate testosterone level (<0.5 ng/ml) were reviewed. Antiandrogen withdrawal syndrome had been tested before the switch. Degarelix was administered as followed: 240 mg for the first injection and then 80 mg every month, subcutaneously. We evaluated the PSA and testosterone level variation 3 months after the switch. Patients who experienced a variation in PSA of less than 10% compared to the baseline or who had a more than 10% PSA decrease were defined as responders. RESULTS: Mean PSA level at the switch was 34.3 ± 50.3 ng/ml, with a mean testosterone level of 0.21 ± 0.13 ng/ml. Three months after the switch, mean PSA level was 59.9 ± 81.6 ng/ml (P = 0.061), with a mean testosterone level of 0.19 ± 0.08 ng/ml (P = 0.086). At 3 months, 4 patients (23%) responded to therapy. Thirteen patients (77%) experienced a rise in PSA of more than 10% compared to baseline; 41% of patients decreased their testosterone level. The limitations of this study are its retrospective nature and the limited number of patients. CONCLUSION: Switch from an agonist to an antagonist of GnRH has a limited impact on PSA at 3 months in castration-resistant prostate cancer patients.
Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Oligopéptidos/uso terapéutico , Neoplasias de la Próstata/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Progresión de la Enfermedad , Sustitución de Medicamentos , Hormona Liberadora de Gonadotropina/agonistas , Humanos , Calicreínas/sangre , Masculino , Antígeno Prostático Específico/sangre , Estudios Retrospectivos , Testosterona/sangre , Resultado del TratamientoRESUMEN
Ureterohydronephrosis of the lower segment in a context of ureteric duplication is a rare entity and is usually associated with vesicoureteric reflux. The authors report the case of a 35-year-old woman with giant ureterohydronephrosis of the lower segment secondary to partial ureteric duplication due to primary megaureter discovered in a context of infection. After primary percutaneous drainage of the collection, treatment consisted of partial nephrectomy with preservation of the good quality upper segment.